| Autor: |
Ralph A. Tripp, Jackelyn Murray, Kathy Blahunka, Robert J. Hogan, Fred Sancillo, Mark Lovern, Rajiv Balyan, Richard Still, David E. Martin |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.05.21.445119 |
| Popis: |
Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
